Enoblituzumab

Generic Name: Enoblituzumab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1353485-38-7

Unique Ingredient Identifier: M6030H73N9

Background: Enoblituzumab is under investigation in clinical trial NCT02982941 (Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer

Phase 2

Recruiting

Conditions: Prostate Cancer

Interventions: Other: Standard of Care
Drug: Enoblituzumab

First Posted Date: 2023-08-28

Last Posted Date: 2024-10-29

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 219

Registration Number: NCT06014255

Locations: 🇺🇸
Northewestern University, Chicago, Illinois, United States
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
XCancer - Omaha, LLC, Omaha, Nebraska, United States

and more 2 locations

FT516 and IL2 With Enoblituzumab for Ovarian Cancer

Phase 1

Completed

Conditions: Ovarian Cancer
Fallopian Tube Adenocarcinoma
Primary Peritoneal Cavity Cancer

Interventions: Drug: IP FT516
Drug: IL-2
Drug: Enoblituzumab

First Posted Date: 2020-11-16

Last Posted Date: 2023-04-03

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 3

Registration Number: NCT04630769

Locations: 🇺🇸
University of Minnesota, Masonic Cancer Center, Minneapolis, Minnesota, United States

Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors

Phase 1

Completed

Conditions: Neuroblastoma
Rhabdomyosarcoma
Osteosarcoma
Ewing Sarcoma
Wilms Tumor
Desmoplastic Small Round Cell Tumor

Interventions: Drug: Enoblituzumab

First Posted Date: 2016-12-06

Last Posted Date: 2022-02-08

Lead Sponsor: MacroGenics

Target Recruit Count: 25

Registration Number: NCT02982941

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Seattle Children's, Seattle, Washington, United States
🇺🇸
National Cancer Institute, Center for Cancer Research, Bethesda, Maryland, United States

and more 3 locations

Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Enoblituzumab

First Posted Date: 2016-10-04

Last Posted Date: 2024-06-14

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 33

Registration Number: NCT02923180

Locations: 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy